A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant mycobacterium tuberculosis

Science Translational Medicine

Volumn 2, Issue 53, 2010, Pages

  Bertholet, Sylvie ^a,c   Ireton, Gregory C ^a   Ordway, Diane J ^b   Windish, Hillarie Plessner ^a   Pine, Samuel O ^a   Kahn, Maria ^a   Phan, Tony ^a   Orme, Ian M ^b   Vedvick, Thomas S ^a   Baldwin, Susan L ^a   Coler, Rhea N ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BCG VACCINE; FUSION PROTEIN PLUS ADJUVANT; GAMMA INTERFERON; HYBRID PROTEIN; ID 93; ID 93 GLA SE VACCINE; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; PHOSPHORYL LIPID A; RECOMBINANT PROTEIN; SODIUM CHLORIDE; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FEMALE; GUINEA PIG; HAPLORHINI; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MOUSE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SINGLE DRUG DOSE; TH1 CELL; TUBERCULOSIS; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; MYCOBACTERIUM BOVIS;

ANIMALS; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GUINEA PIGS; HAPLORHINI; HUMANS; INTERLEUKIN-2; MICE; MYCOBACTERIUM BOVIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77958047728     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001094     Document Type: Article

References (27)

1. World Health Organization, Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report (World Health Organization, Geneva, Switzerland, 2008).
2. P. Andersen, T. M. Doherty, The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3, 656-662 (2005).
3. J. L. Flynn, J. Chan, Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129 (2001).
4. S. Bertholet, G. C. Ireton, M. Kahn, J. Guderian, R. Mohamath, N. Stride, E. M. Laughlin, S. L. Baldwin, T. S. Vedvick, R. N. Coler, S. G. Reed, Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181, 7948-7957 (2008).
5. R. C. Anderson, C. B. Fox, T. S. Dutill, N. Shaverdian, T. L. Evers, G. R. Poshusta, J. Chesko, R. N. Coler, M. Friede, S. G. Reed, T. S. Vedvick, Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B Biointerfaces 75, 123-132 (2010).
6. S. L. Baldwin, N. Shaverdian, Y. Goto, M. S. Duthie, V. S. Raman, T. Evers, F. Mompoint, T. S. Vedvick, S. Bertholet, R. N. Coler, S. G. Reed, Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27, 5956-5963 (2009).
7. S. Olugbile, C. Kulangara, G. Bang, S. Bertholet, E. Suzarte, V. Villard, G. Frank, R. Audran, A. Razaname, I. Nebie, O. Awobusuyi, F. Spertini, A. V. Kajava, I. Felger, P. Druilhe, G. Corradin, Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c. Infect. Immun. 77, 5701-5709 (2009).
8. S. L. Baldwin, S. Bertholet, M. Kahn, I. Zharkikh, G. C. Ireton, T. S. Vedvick, S. G. Reed, R. N. Coler, Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27, 3063-3071 (2009).
9. S. Bertholet, Y. Goto, L. Carter, A. Bhatia, R. F. Howard, D. Carter, R. N. Coler, T. S. Vedvick, S. G. Reed, Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27, 7036-7045 (2009).
10. S. G. Reed, R. N. Coler, W. Dalemans, E. V. Tan, E. C. DeLa Cruz, R. J. Basaraba, I. M. Orme, Y. A. Skeiky, M. R. Alderson, K. D. Cowgill, J. P. Prieels, R. M. Abalos, M. C. Dubois, J. Cohen, P. Mettens, Y. Lobet, Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl. Acad. Sci. U.S.A. 106, 2301-2306 (2009).
11. A. Weinrich Olsen, L. A. van Pinxteren, L. Meng Okkels, P. Birk Rasmussen, P. Andersen, Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69, 2773-2778 (2001).
12. B. Wang, M. Henao-Tamayo, M. Harton, D. Ordway, C. Shanley, R. J. Basaraba, I. M. Orme, A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin. Vaccine Immunol. 14, 902-906 (2007).
13. J. Dietrich, C. Aagaard, R. Leah, A. W. Olsen, A. Stryhn, T. M. Doherty, P. Andersen, Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: Efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174, 6332-6339 (2005).
14. M. E. Polhemus, S. A. Remich, B. R. Ogutu, J. N. Waitumbi, L. Otieno, S. Apollo, J. F. Cummings, K. E. Kester, C. F. Ockenhouse, A. Stewart, O. Ofori-Anyinam, I. Ramboer, C. P. Cahill, M. Lievens, M. C.Dubois, M.A. Demoitie, A. Leach, J. Cohen, W. R. Ballou,D.G.Heppner Jr., Evaluation of RTS, S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 4, e6465 (2009).
15. K. Von Eschen, R.Morrison, M. Braun, O. Ofori-Anyinam, E. De Kock, P. Pavithran, M. Koutsoukos, P. Moris, D. Cain, M. C. Dubois, J. Cohen, W. R. Ballou, The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum. Vaccin. 5, 475-482 (2009).
16. I. D. Vélez, K. Gilchrist, S. Martínez, J. R. Ramírez-Pineda, J. A. Ashman, F. P. Alves, R. N. Coler, L. Y. Bogatzki, S. J. Kahn, A. M. Beckmann, K. D. Cowgill, S. G. Reed, F. M. Piazza, Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28, 329-337 (2009).
17. M. Okada, Y. Kita, T. Nakajima, N. Kanamaru, S. Hashimoto, T. Nagasawa, Y. Kaneda, S. Yoshida, Y. Nishida, H. Nakatani, K. Takao, C. Kishigami, Y. Inoue, M. Matsumoto, D. N. McMurray, E. C. Dela Cruz, E. V. Tan, R. M. Abalos, J. A. Burgos, P. Saunderson, M. Sakatani, Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 27, 3267-3270 (2009).
18. R. J. Basaraba, A. A. Izzo, L. Brandt, I. M. Orme, Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 24, 280-286 (2006).
19. J. Dietrich, R. Billeskov, T. M. Doherty, P. Andersen, Synergistic effect of bacillus Calmette Guerin and a tuberculosis subunit vaccine in cationic liposomes: Increased immunogenicity and protection. J. Immunol. 178, 3721-3730 (2007).
20. C. Rouanet, A. S. Debrie, S. Lecher, C. Locht, Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect. 11, 995-1001 (2009).
21. N. P. Goonetilleke, H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, A. V. Hill, Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602-1609 (2003).
22. L. Brandt, Y. A. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, S. G. Reed, I. M. Orme, The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72, 6622-6632 (2004).
23. Y. A. Skeiky, J. Dietrich, T. M. Lasco, K. Stagliano, V. Dheenadhayalan, M. A. Goetz, L. Cantarero, R. J. Basaraba, P. Bang, I. Kromann, J. B. McMclain, J. C. Sadoff, P. Andersen, Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 28, 1084-1093 (2010).
24. Z. Xing, C. T. McFarland, J. M. Sallenave, A. Izzo, J. Wang, D. N. McMurray, Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 4, e5856 (2009).
25. D. Gaucher, R. Therrien, N. Kettaf, B. R. Angermann, G. Boucher, A. Filali-Mouhim, J. M. Moser, R. S. Mehta, D. R. Drake III, E. Castro, R. Akondy, A. Rinfret, B. Yassine-Diab, E. A. Said, Y. Chouikh, M. J. Cameron, R. Clum, D. Kelvin, R. Somogyi, L. D. Greller, R. S. Balderas, P. Wilkinson, G. Pantaleo, J. Tartaglia, E. K. Haddad, R. P. Sékaly, Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119-3131 (2008).
26. J. T. van Dissel, S. M. Arend, C. Prins, P. Bang, P. N. Tingskov, K. Lingnau, J. Nouta, M. R. Klein, I. Rosenkrands, T. H. Ottenhoff, I. Kromann, T. M. Doherty, P. Andersen, Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 28, 3571-3581 (2010).
27. P. M. Small, R. W. Shafer, P. C. Hopewell, S. P. Singh, M. J. Murphy, E. Desmond, M. F. Sierra, G. K. Schoolnik, Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328, 1137-1144 (1993).